Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

BRNS - Barinthus Biotherapeutics Plc. - ADR


IEX Last Trade
1.315
0.035   2.662%

Share volume: 2,722
Last Updated: Fri 30 Aug 2024 09:59:50 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$1.28
0.04
2.73%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
18%
Profitability 15%
Dept financing 3%
Liquidity 75%
Performance 10%
Company vs Stock growth
vs
Performance
5 Days
10.50%
1 Month
-12.33%
3 Months
-34.25%
6 Months
-53.37%
1 Year
-34.58%
2 Year
-70.78%
Key data
Stock price
$1.32
P/E Ratio 
-0.73
DAY RANGE
N/A - N/A
EPS 
-$1.83
52 WEEK RANGE
$1.18 - $5.10
52 WEEK CHANGE
-$0.36
MARKET CAP 
51.830 M
YIELD 
N/A
SHARES OUTSTANDING 
39.415 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
0.65
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$17,049
AVERAGE 30 VOLUME 
$13,326
Company detail
CEO:
Region: US
Website: vaccitech.co.uk
Employees: 109
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

vaccitech is a spin-out company from the university of oxford’s jenner institute, one of the oldest and most renowned vaccine research centres in the world. the company has been formed around two viral vector vaccines, one to prevent influenza and the other to treat prostate cancer. viral vector vaccines are particularly good at treating some of the most recalcitrant illnesses. the underlying technology is built on years of experience perfecting viral vector vaccine technology across multiple indications. the company’s protected chimpanzee adenovirus technology is the best way to generate t-cell responses and thereby generate lasting cell-mediated immunity. the assets are already in the clinic with very promising initial results. the founders of the company are professor adrian hill (director of the jenner institute) and professor sarah gilbert (lead in influenza and mers), who combine their exceptional scientific skills with regulatory and manufacturing experience. this autumn, vaccit

Recent news